Novo Seeds, the early-stage investment and company creation team of Novo Holdings, … Continue reading “Novo Seeds’ portfolio company, IO Biotech, completes oversubscribed EUR 127m Series B financing to accelerate clinical programs in oncology”
Neuraxpharm launches first product in Japan Launch of Buccolam® – market leading … Continue reading “NEURAXPHARM LAUNCHES FIRST PRODUCT IN JAPAN”
Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing … Continue reading “Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer”
Dr Klaas Zuideveld appointed as Chief Executive Officer to accelerate the development … Continue reading “Versameb Announces Management Update”
Novo Ventures, the ventures arm of Novo Holdings, today announces its participation … Continue reading “Novo Holdings participates in BioGeneration Ventures IV Fund”
Turbine, a company simulating cellular decision making to unlock novel oncology therapies, … Continue reading “Turbine Raises EUR 5.7M to Advance Simulation-first Oncology Pipeline”
Novo Seeds, the early stage investment and company creation team of Novo … Continue reading “Novo Seeds portfolio company CorWave raises EUR 35m for breakthrough heart pump”
Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of … Continue reading “Destiny Pharma Update on the recently acquired NTCD-M3 programme”
Gothenburg, December 21, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical … Continue reading “Positive results show that C21 can become an important complement to COVID-19 vaccines”
MinervaX, a privately held Danish biotechnology company developing a novel vaccine against … Continue reading “MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials”
Today the Novo Holdings REPAIR Impact Fund announces a further investment in … Continue reading “REPAIR Impact Fund supports upsized MinervaX EUR 47.4m Series B financing to advance novel vaccine against Gr. B Streptococcus”
Neuraxpharm acquires Medinutrix Ltd to provide an immediate platform for the recently … Continue reading “Neuraxpharm establishes operations in the Republic of Ireland through the acquisition of Medinutrix”
Funded through Novo Seeds’ company creation and building efforts Focus on rare … Continue reading “Novo Holdings Creates New Rare Bleeding Disorder Company, Hemab”
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its … Continue reading “Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates”
With continued positive development, The Novo Nordisk Foundation can provide up to … Continue reading “The Novo Nordisk Foundation establishes BioInnovation Institute as an independent foundation”
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing … Continue reading “Futura provides US regulatory and commercial update”
Oral C21 treatment demonstrates significant clinical improvement on top of corticosteroids Gothenburg, … Continue reading “Vicore Pharma reports positive top line data from the ATTRACT clinical study in patients with COVID-19”
Three-year strategic research collaboration to discover and develop multiple precision oncology drugs … Continue reading “Artios and Merck KGaA announce global strategic collaboration”
Developing STING Antagonist for Treatment of Severe Lupus New Investment by Novo Holdings … Continue reading “ISD Immunotech, a Novo Seeds portfolio company, enters strategic research collaboration for the development of a novel lupus treatment”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2N 2AT
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
